Chief Executive Officer

• Mr. Bramlage was the Chief Executive Officer of Pearl Therapeutics from 2011 through 2016 and which was sold in 2013 to Astra Zeneca for up to $1.15 billion
• Previous positions included: COO of Pharmaceutical Products at Covidien plc., President of European operations at Valeant Pharmaceuticals International, President/CEO of BattellePharma, Inc., Vice President of Respiratory Global Commercial Development and Vice President of U.S. respiratory and cardiovascular marketing for GlaxoSmithKline
• Mr. Bramlage has been involved in 28 product launches in 15 therapeutic areas
• Mr. Bramlage holds an MBA from the University of Dayton and a BS Administrative Science in Marketing from The Ohio State University